SANA
$3.22
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Intraday
Recent News
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index gaining 0.2% an
Sector Update: Health Care Stocks Advance Friday Afternoon
Health care stocks rose Friday afternoon, with the NYSE Health Care Index increasing 0.3% and the St
Sana: Q4 Earnings Snapshot
SEATTLE (AP) — Sana Biotechnology Inc. SANA) on Tuesday reported a loss of $58.8 million in its fourth quarter. The Seattle-based company said it had a loss of 21 cents per share.
Sana Biotechnology, Inc. (SANA): A Bull Case Theory
We came across a bullish thesis on Sana Biotechnology, Inc. on Stock Invader’s Substack. In this article, we will summarize the bulls’ thesis on SANA. Sana Biotechnology, Inc.’s share was trading at $4.00 as of February 9th. Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. SANA has emerged as a […]